Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.

Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström K.

Transl Oncol. 2011 Aug;4(4):212-21. Epub 2011 Aug 1.

2.

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K.

J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.

3.

Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers.

Bjartell A, Montironi R, Berney DM, Egevad L.

Acta Oncol. 2011 Jun;50 Suppl 1:76-84. doi: 10.3109/0284186X.2010.531284. Review.

PMID:
21604944
4.

Tumor markers in prostate cancer I: blood-based markers.

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.

Acta Oncol. 2011 Jun;50 Suppl 1:61-75. doi: 10.3109/0284186X.2010.542174. Review.

5.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE; SPCG-4 Investigators.

N Engl J Med. 2011 May 5;364(18):1708-17. doi: 10.1056/NEJMoa1011967.

6.

Global cancer statistics.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.

7.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

8.

Estimates of cancer incidence and mortality in Europe in 2008.

Ferlay J, Parkin DM, Steliarova-Foucher E.

Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.

PMID:
20116997
9.

A new generation of proto-oncogenes: cold-inducible RNA binding proteins.

Lleonart ME.

Biochim Biophys Acta. 2010 Jan;1805(1):43-52. doi: 10.1016/j.bbcan.2009.11.001. Epub 2009 Nov 10. Review.

PMID:
19900510
10.

The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death.

Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Bührer C.

Pediatr Res. 2010 Jan;67(1):35-41. doi: 10.1203/PDR.0b013e3181c13326.

PMID:
19770690
11.

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.

Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.

12.

Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.

Zeng Y, Kulkarni P, Inoue T, Getzenberg RH.

J Cell Biochem. 2009 May 1;107(1):179-88. doi: 10.1002/jcb.22114.

13.

The Human Protein Atlas--a tool for pathology.

Pontén F, Jirström K, Uhlen M.

J Pathol. 2008 Dec;216(4):387-93. doi: 10.1002/path.2440.

PMID:
18853439
14.

Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe.

Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, Houchen CW, Anant S.

Oncogene. 2008 Jul 31;27(33):4544-56. doi: 10.1038/onc.2008.97. Epub 2008 Apr 21.

15.

A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues.

Björling E, Lindskog C, Oksvold P, Linné J, Kampf C, Hober S, Uhlén M, Pontén F.

Mol Cell Proteomics. 2008 May;7(5):825-44. Epub 2007 Oct 3.

16.

DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy.

Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J.

Int J Androl. 2007 Aug;30(4):282-91; discussion 291. Epub 2007 Jun 15.

PMID:
17573848
17.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I.

J Urol. 2007 Feb;177(2):540-5. Review.

PMID:
17222629
18.

A human protein atlas for normal and cancer tissues based on antibody proteomics.

Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergström K, Brumer H, Cerjan D, Ekström M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Björklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Sköllermo A, Steen J, Stenvall M, Sterky F, Strömberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Waldén A, Wan J, Wernérus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Pontén F.

Mol Cell Proteomics. 2005 Dec;4(12):1920-32. Epub 2005 Aug 27.

19.

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD.

Nature. 2005 Apr 14;434(7035):907-13.

PMID:
15829965
20.

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J.

Nature. 2005 Apr 14;434(7035):864-70.

PMID:
15829956

Supplemental Content

Support Center